Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure.

Echoing that sentiment, Rosen pointed to mounting calls for the FDA to fund and oversee phase 4 postmarketing studies that actually have some teeth.